Vitexin has a cytotoxic effect on breast, ovary, and prostate cancer cells by upregulating BCL2-associated X protein (Bax) and downregulating BCL2 and causing the breakage of the poly[adenosine diphosphate (ADP)-ribose] polymerase (PARP) protein [121]. The gene discussed is BAX; the disease is prostate cancer.